Kalaris Therapeutics, Inc. Common Stock (KLRS) Stock
NASDAQ · KLRS
3.20
Fundamentals
Market cap
$76.18M
Price / Earnings ratio
-1.7x
Price / Sales ratio
N/A
Price / Book ratio
1.3x
Return on assets
-0.4%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Kalaris Therapeutics, Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
SectorHealthcare
IndustryBiotechnology
Employees20
CEOMr. Andrew Oxtoby
IPO DateJul 30, 2020
HeadquartersBerkeley Heights, NJ
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Andrew Oxtoby | President, CEO & Director | 1974 |
| Dr. Srinivas Akkaraju M.D., Ph.D. | Director & Co-Founder | 1968 |
| Dr. Michael Philip Dybbs Ph.D. | Co-Founder & Director | 1975 |
| Dr. Napoleone Ferrara M.D. | Independent Director & Co-Founder | 1957 |
| Dr. Matthew Feinsod M.D. | Chief Medical Officer | 1971 |
| Ms. Liisa Ann Bayko M.B.A. | CFO & Treasurer | 1971 |
| Ms. Amy Vandekop | Interim Principal Accounting Officer & Corporate Controller | 1989 |
| Ms. Kristine Curtiss | Senior Vice President of Clinical | — |
| Dr. Jill E. Porter Ph.D. | Senior Vice President of CMC | — |
Fundamentals
Valuation
Market cap$76.18M
Price-to-sales ratioN/A
Price-to-book value1.30
Price-earnings ratio-1.70
Return on Equity-73.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-2.02
Income Statement
Average volume58,123
EBITDA$-43.98M
1 year high (52w)$11.88
1 year low (52w)$3.03
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



